Roche’s faricimab meets primary endpoint in DME trial

Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more

Myopia Profile and CORE join forces

The world’s largest childhood myopia education resource developed by Australian optometry couple Dr Kate and Dr Paul Gifford has formed a new alliance with the renowned Centre for Ocular Research & Education (CORE). Read more